Pfizer
Pfizer Trims 200 Positions at Michigan COVID Plant During Cost-Saving Measures
The decline in demand for its COVID-19 treatments has prompted Pfizer to initiate a cost-reduction strategy across the company, which ...
GSK’s Arexvy Vaccine Poised for Blockbuster Sales, Besting Pfizer in RSV Market Debut
Pfizer is facing not only a decline in its COVID-19 vaccine sales but also stiff competition from GSK in the ...
Pfizer Announces New Jersey Site Closure and Layoffs in $3.5B Cost-Cutting Initiative
The financial ramifications of Pfizer’s revenue decline due to the COVID-19 pandemic are now revealing their human toll as the ...
Merck boosts revenue outlook on COVID-19 pill Lagevrio demand
In a surprising turn of events, Merck’s COVID-19 antiviral pill, Lagevrio, has defied expectations by generating an astounding $640 million ...
Pfizer, BioNTech ready flu-COVID combo vaccine for phase 3 trial
In an exciting race reminiscent of their previous encounters, Pfizer and BioNTech have once again taken on their recurring competitor, ...
GSKās RSV vaccine poised for label expansion after trial success
Five months after GSK made history by securing FDA approval for its respiratory syncytial virus (RSV) vaccine, Arexvy, the company ...
Pfizer Faces Backlash for Raising Price of Covid Drug Paxlovid
Following Pfizer’s announcement to increase the cost of its COVID-19 treatment drug, Paxlovid, for the next year, the AIDS Healthcare ...
Roche’s $7B Investment Ignites Intense Competition with Merck in the Bowel Disease Market Amid TL1A Feeding Frenzy
Roche has made a substantial move by agreeing to pay Roivant and Pfizer $7.1 billion upfront for regional rights to ...
Pfizerās Penbraya: First vaccine to prevent all five types of meningitis gets FDA approval
Pfizer has secured a significant regulatory victory in the race to introduce the first five-pronged meningitis vaccine in the United ...
Pfizer agrees to pay $300,000 to resolve gender pay bias claims at NYC HQ
Pfizer has agreed to a $2 million settlement to resolve allegations made by the US Department of Labor, which claimed ...
Pfizer Reduces Revenue Projection by $9 Billion Due to Declining COVID Sales, Prepares for Substantial Cost Reductions
As the COVID-19 pandemic transitions into an endemic phase, pharmaceutical companies have been bracing for a decline in demand for ...
Pfizerās Velsipity gets FDA approval to challenge BMSā Zeposia in ulcerative colitis market
Pfizer’s groundbreaking approval of its drug, Velsipity, as a once-daily oral treatment for adults suffering from moderate to severe active ...
Pfizer agrees to pay $50M to settle EpiPen price-fixing lawsuit
Pfizer has agreed to a $50 million settlement to resolve a class-action antitrust case dating back to 2020. The lawsuit, ...
Pfizer gets FDA nod for Lorbrena-Vizimpro combo to treat advanced lung cancer
Pfizer is making strategic moves to reinforce its presence in the oncology arena, with the FDA granting approval for its ...
Novavax partners with TV show star to promote COVID-19 vaccine choice and awareness
Novavax is gearing up for a robust marketing push to secure a share of the COVID-19 booster vaccine market this ...
Lagevrio, the first oral COVID-19 drug, to be available in US soon
As anticipated, the US government is in the process of phasing out its distribution of COVID-19 treatments. Merck & Co.’s ...
Pfizer’s Hospira Initiates Recall of 3 Drug Lots Due to Particulate Concerns
Hospira, a subsidiary of Pfizer, has taken the proactive step of issuing a voluntary recall for specific injectable medications, namely ...
ICER Reviews BMS’ Eliquis, J&J’s Xarelto Amidst Medicare Price Talks
As the United States embarks on a new era of drug price negotiations, the Institute for Clinical and Economic Review ...
Pfizer Collaborates with Ginkgo in a $331 Million Biobucks Partnership
Ginkgo Bioworks has secured a substantial partnership with pharmaceutical giant Pfizer, marking a significant milestone in its portfolio of collaborations. ...
Merckās antiviral pill Lagevrio may have triggered new COVID variants, study suggests
As concerns about the coronavirus continue to loom, the spotlight is once again on the most widely used oral antiviral ...
Pfizer resumes most of its drug production at tornado-damaged North Carolina plant
In the wake of a devastating summer tornado that struck Pfizer’s Rocky Mount injectables plant in North Carolina, significant strides ...
Pfizer’s Abrysvo Secures CDC Endorsement for Infant Protection, Intensifying RSV Vaccine Competition
Despite GSKās Arexvy pioneering the respiratory syncytial virus (RSV) vaccine landscape earlier this summer, Pfizer has persistently challenged the competition ...
Padcev-Keytruda combo cuts death risk in first-line bladder cancer
As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...
Pfizerās tafamidis faces competition from Alnylam and BridgeBio in rare disease market
Alnylam and BridgeBio are poised to enter the highly lucrative transthyretin amyloidosis cardiomyopathy (ATTR-CM) market with the backing of an ...
Pfizerās Nurtec gets thumbs up from NICE for migraine attacks
England’s National Institute of Care and Health Excellence (NICE) has granted approval for Pfizer’s Vydura (rimegepant) as a treatment for ...
Pfizer CEO supports migraine sufferers and urges employers to do the same
Pfizer’s CEO, Dr. Albert Bourla, is championing a disease awareness campaign by leveraging his social media platforms to underscore the ...
Pfizerās Lyme Vaccine Shows Strong Booster And Pediatric Effects In Phase 2
Pfizer and Valneva are making strides in their Lyme disease vaccine program, achieving a significant milestone by demonstrating the safety ...
Nimbus Raises $210M To Advance Small Molecule Pipeline, Honors Late Founder
Nimbus Therapeutics, with its experienced leadership, well-established R&D platform, and substantial financing, appears well-positioned for success in the public markets. ...
Pfizer and BioNTech Get Green Light for Omicron Vaccine in Europe by CHMP
Pfizer and BioNTech have unveiled their latest breakthrough in the post COVID era. Brace yourselves for the Omicron XBB.1.5-adapted monovalent ...
Pfizer and BioNTech challenge Modernaās mRNA vaccine patents in a bid to end monopoly
The legal battle between Moderna and its rivals Pfizer and BioNTech over the patents related to mRNA vaccine production is ...
